MedTrace Logo

Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy

NCT01959269 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 483

Last updated 2018-03-08

No results posted yet for this study

Summary

The purpose of the study is to investigate the safety and effectiveness of Stivarga in patients with metastatic colorectal carcinoma in routine use in Germany. The study is purely observational, only data from routine treatment are to be collected. The treatment and treatment conditions are solely at discretion of the treating physician.

Conditions

  • Colorectal Neoplasm

Interventions

DRUG

Regorafenib (Stivarga, BAY 73-4506)

As determined by the treating physician

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2017-03-31
Completion
2017-07-07

Countries

  • Germany

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01959269 on ClinicalTrials.gov